Russell J. Mumper, Ph.D.

Curriculum Vitae
June, 2016

PERSONAL INFORMATION:

Work Address: Russell J. Mumper, Ph.D.
Vice Provost for Academic Affairs

University of Georgia
204 Administration Building
220 South Jackson Street
Athens, GA 30602
Phone: (706) 542-5806
E-mail: mumper@uga.edu

Home Address: 1230 Hammond Creek Trail, Watkinsville, Georgia, 30677
Marital Status: Married (1990) to Natalie A. Pascuzzi (Registered Nurse)
Children: Ryan, Shannon, and Erin
Birth Place: West Bend, Wisconsin

PROFESSIONAL HIGHLIGHTS:

Employment:

University of Georgia (2014-present)
University of North Carolina at Chapel Hill (2007-2014)
University of Kentucky (1999-2007)
ViroTex Corporation (1998-1999)
GeneMedicine Inc. (1994-1998)
Burroughs Wellcome Co. (1992-1994)

Management & Leadership Experience:

- Campuswide administration of programs and initiatives relating to faculty and academic affairs
- University-wide oversight over SACSCOC accreditation and University SACSCOC Liaison
- Member of SACSCOC off-site review team
- Member of The University Cabinet, advisory to the President
- Chair, Executive Committee, Environmental Health and Safety Management System
- Chief Academic and Strategic Officer of a research-intensive health sciences school
- Leadership of R&D and FDA-registered cGMP pharmaceutical manufacturing center
- Strategic and Business Plans for academic units, centers, companies, and university
- Co-founder of 5 start-up companies; member of BODs for angel and VC-backed companies
- Write U.S. and foreign patent applications and respond to office actions
- Expert patent witness including expert reports, deposition, and witness in federal trials
- Member of federal (NIH, DOD, and NSF) Scientific Review Panels
- Consultant to the pharmaceutical & biotechnology industries
- Business/technology negotiations leading to contracts, licenses and MOUs
- Creation and development of multiple Public/Private Partnerships

Academic & Research Experience:

- Recipient of two campuswide teaching awards at two different R1 universities
- Educational research relating to the Flipped Classroom
- Nanotechnology (nano-based delivery systems and nano-based sensors) and nanotoxicology
- Cell- and tissue-specific targeting (e.g., dendritic cells, tumor cells, blood-brain barrier)
- Vaccine delivery systems; genetic and subunit immunization; microbicide development
- Pharmaceutical R&D and product development
- Over $10.2M in grants/contracts as Principal Investigator (and >$28.7M total) in 15 years
- Awarded/Completed 42 grants/contracts from Federal/Foundation sources and 41 from Industry
- Over 300 scientific publications/abstracts and over 49 patents or patent families pending
- Citation Report (Google Scholar): *h*-index: 55; i10-index: 106; Sum of Times Cited: 9588

EDUCATION:

1991 – 1992 Postdoctoral Fellowship, Protein Drug Delivery
Center for Bioengineering, University of Washington, Seattle, Washington
Advisor: Allan S. Hoffman, Sc.D., Professor, Bioengineering and Chemical Engineering

1991 Ph.D., Pharmaceutical Sciences (Pharmaceutics/Drug Delivery)
College of Pharmacy, University of Kentucky, Lexington, Kentucky
Advisor: Michael Jay, Ph.D., Professor, Pharmaceutical Sciences
Dissertation Title: "Biodegradable Polyester Microspheres Containing Neutron Activable Rare-Earths for Internal Radiation Therapy."

1988 B.A., Chemistry, with High Distinction and Departmental Honors
University of Kentucky, Lexington, Kentucky

ACADEMIC PROFESSIONAL EXPERIENCE:

2014 – present **University of Georgia, Athens, Georgia**

Vice Provost for Academic Affairs (August 2014- present)
The Vice Provost has the following responsibilities at the University of Georgia:

- UGA Accreditation: University point-person for accreditation for the University of Georgia and Accreditation Liaison to SACSCOC
- UGA Strategic Plan: Oversight and monitoring of progress of UGA's 2020 Strategic Plan: Building on Excellence
- UGA Program Review: Oversight over the entire Program (Academic and Support Unit) Review process at the University of Georgia
- Operationalize major initiatives originating from the Provost's Office
- Advise the Provost on several key academic appointments and appeals processes as well as faculty development, promotion and tenure, and related issues
- Collaborate with Deans, Vice Presidents and Associate Provosts and units that report to the Provost's Office
- Chair, UGA Arts Council
- Chair, Executive Committee, Environmental Health and Safety Management System
- On behalf of the President and Provost, review and render final decisions on student appeals in matters of academic honesty at the University of Georgia
- Provide oversight over the following Offices/Programs:
  - Georgia Museum of Art
  - Institute of Higher Education
  - UGA Performing Arts Center
  - Skidaway Institute of Oceanography
  - Office of Accreditation
  - University-wide Program (Academic and Support Unit) Review
- Serve on The University Cabinet, which functions as the University's official policy-making body, advisory to the President
- Chair of other university-wide committees

Highlights of major initiatives successfully led and/or completed (2014 – present):

- Campuswide review and recommendations for the Environmental Safety Division, especially relating to UGA's Comprehensive Environmental Health and Safety Management Plan (2014)
- Campuswide revisions of all 82 promotion and tenure documents at UGA (2015)
- Developed and implemented a centralized classroom scheduling system at UGA (2015)
- Developed new UGA policy for faculty outside work for pay (2015)
- Developed new UGA policy for assessment of all academic programs (2016)

- Validated UGA's Signature Research Themes with Academic Analytics® (2015)
- Expanded programming for UGA's annual Spotlight on the Arts Festival (2014, 2015)

2014 – present Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy
Professor, College of Engineering

2007 – 2014 **UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina**

Vice Dean (2010-2014)

- Served as the chief academic and strategic officer of the School with wide range of responsibilities that spanned all missions and interfaced with all units, divisions, and centers/institutes
- Supported the dean operationally within the School and the University, and substituted for the Dean, as required
- Facilitated all MOUs and MOAs between School and other University units
- Chaired the Executive Committee meetings
- Chaired the Full Professors Committee
- Functioned as the Equal Employment Opportunity Officer for the School
- Functioned as the curator of key School documents including the Strategic Plan, Faculty Code (Governance Document), and Policies and the Procedures Governing Appointments, Reappointments, Promotion, and Tenure for Faculty in the School
- Oversaw and approved External Professional Activities for Pay for Faculty in the School
- Functioned as the Initial leader for new initiatives including InfoPorte™ and the Cooperative Business Cluster Model. InfoPorte is a web-based portal developed in 2007 that provides a consolidated view of all financial and human resource information from various University systems. InfoPorte is now used throughout the campus and is being integrated with PeopleSoft. The Cooperative Business Cluster Model was the consolidation of subject-matter experts in finance, human resources, IT, and pre- and post-awards into service teams that worked with faculty and staff to enhance operational efficiencies in an academic research environment.
- Served as the liaison with the University regarding implementation of University-wide program activities
- Managed areas that cut across professional education and graduate education, such as instructional technology, distance education, and programmatic expansion
- Provided assistance to the division chairs with faculty recruitment processes
- Oversaw the Appointment, Reappointment, Promotion, and Tenure process in the School
- Provided oversight of the following Offices/Institutes/Programs:

    - Office of Strategic Planning and Assessment. I co-chaired the creation of the School's 2012-2017 Strategic Plan, which framed the School's $100 million capital campaign.
    - *The Academy* at the UNC Eshelman School of Pharmacy, an Institute which includes the Office of Educational Technology R&D. I provided the vision for and led the establishment of *The Academy* and wrote the Instructional Innovation Policy and Participation Agreement which served as a vehicle for faculty to engage in highly innovative educational offerings that were aligned with the School's appointment, promotion, and tenure policies.
    - Office of Continuing Education
    - Office of Innovative Leadership and Diversity. I led the drafting of Strategic Initiative 6 in the Strategic Plan titled "Our People." Two guiding principles include i) the recruitment of faculty and staff into career opportunities, not just jobs, and ii) the School's aspiration to be a diverse community of people having the core value that a diversity of views, gender, races, ethnic backgrounds, and experiences of its faculty, staff and students is vital to allow the school to execute its mission to develop leaders who have a positive impact on human health worldwide.
    - Bill and Karen Campbell Faculty Mentoring Program

John A. McNeill Distinguished Professor, Division of Molecular Pharmaceutics (2007-2014)
Research programs were focused primarily in five areas including; 1) nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles for tumor and dendritic cell targeting and vaccines, 2) biocompatibility, hemocompatibility, and toxicology of nanoparticles and nanomaterials, 3) antibody-drug conjugates, 4) mucoadhesive gels, thin-films, and intravaginal rings for (trans)mucosal delivery of drugs, vaccines, and microbicides, and 5) anticancer and anti-inflammatory properties of berries and berry extracts. NIH, NSF, and industrial funding for these programs as well as others are listed under "Research Grants Awarded."

Professor, UNC/NCSU Joint Department of Biomedical Engineering at UNC-Chapel Hill (2010-2014)
Co-Director, UNC Institute for Nanomedicine (2008-2012)
Full Member, UNC Lineberger Comprehensive Cancer Center (2007-2014)
Founding Director, Center for Nanotechnology in Drug Delivery (2007-2012)

1999 – 2007 **College of Pharmacy, University of Kentucky, Lexington, Kentucky**

Vice Chair, Department of Pharmaceutical Sciences (2004-2007)
Associate Professor, Pharmaceutical Sciences (2004-2007): early tenure Jan. 1, 2004

Associate Director, Center for Pharmaceutical Science and Technology (2003-2006)

The Center for Pharmaceutical Science and Technology (CPST) was the College of Pharmacy's analytical and formulation development and FDA-registered cGMP clinical trial manufacturing facility. As Associate Director, I oversaw selected operations of the Center pertaining to Business Development, Formulation Development, consulting, writing grant proposals, and negotiating contracts. As Principal Investigator on many projects, I worked closely with clients, the Director of the CPST and the Managing Director in overseeing all aspects of selected projects to their successful completion. From 1999 to 2006, working with seven different clients, I led the CPST's efforts to complete seven full product development (analytical, formulation, manufacturing, quality control) leading to the successful submission of INDs and commencement of human clinical trials. The CPST became a for-profit company, Coldstream Laboratories Inc., in 2007.

Assistant Professor, Pharmaceutical Sciences (1999-2003)
Assistant Director, Center for Pharmaceutical Science and Technology (1999-2003)

INDUSTRIAL PROFESSIONAL EXPERIENCE:

1998 – 1999 **ViroTex Corporation, The Woodlands, Texas**

Director of Product Development: Designed, optimized, and scaled-up drug delivery systems for skin and mucosal delivery. Developed and validated analytical assays for the development of these delivery systems as products. Delivery systems were primarily polymer-based formulations applied as films, gels, pump sprays, or aerosols. Led research effort on the application of ViroTex's BEMA™ (BioErodible MucoAdhesive) delivery technology for mucosal vaccines based on protein antigens with or without adjuvants. Established and managed two academic collaborations investigating novel mucosal vaccine candidates. Note: ViroTex was sold to Atrix Laboratories, Inc. in Nov. 1998; Atrix was subsequently sold to QLT, Inc. of Canada in 2005.

1994 – 1998 **GeneMedicine Inc., The Woodlands, Texas**
(GeneMedicine merged with Megabios and became Valentis, Inc. in 1999)

Project Team Leader, Infectious Disease Product Discovery (1997-1998): Led a team of scientists involved with the discovery and application of novel genetic vaccines for infectious diseases caused by bacterial and viral pathogens. The lead product target was *Helicobacter*

pylori. The team also assessed the efficacy of proprietary formulations administered with needle-free injection devices to dogs. Responsible for long term technical planning of the projects and for leading discussions with potential corporate partners. Managed two external collaborations with Baylor College of Medicine and MD Anderson Cancer Center.

Project Team Leader, Antigen Presenting Cell (APC) Targeting (1996-1997): Coordinated and directed a team of twelve scientists that worked to target genetic vaccines to immature dendritic cells residing in the skin epidermis (Langerhans cells) and mature dendritic cells in the draining lymph nodes. Managed annual research/personnel budget of $1.75 million.

Group Leader, Polymer Systems Group, Gene Delivery Sciences (1995-1996): Group Leader of five scientists that worked on the discovery of polymeric gene delivery systems including protective, interactive, non-condensing (PINC™) polymers and chitosan-based systems. Coordinated and implemented the synthetic, analytical, and formulation efforts across a matrix of Program Teams (Cancer, Vaccines, Muscle/Growth Factors). Member of the Institutional Animal Care and Use Committee (IACUC).

Senior Scientist, Gene Delivery Department (1994-1995): Led a team of four formulation scientists pursuing the research, development, and scale-up of delivery systems for plasmid DNA. The delivery systems included cell-targeted plasmid complexes, dry powders, protective interactive non-condensing (PINC™) systems, and novel condensing agents such as dendrimers and chitosan analogues. Managed collaborations with two academic groups. Led the discovery, development, and scale-up of a stable, one-vial, lyophilized formulation for human Insulin-like Growth Factor (hIGF-I) Gene Medicine for potential treatment of neuromuscular diseases.

1992 – 1994 **Burroughs Wellcome Co., Pharmaceutical Research and Development Laboratories, Greenville, North Carolina (now GlaxoSmithKline)**

Development Scientist III, Solid Formulation Development, New Products: Designed, manufactured, and optimized oral dosage forms for new chemical entities. Wrote CMC sections for two INDs, sections of one NDA (VALTREX®), and several other regulatory documents. Research focused on solids characterization, solid state stability, and novel drug delivery systems.

FOUNDED START-UP COMPANIES and ENTREPRENERIAL INITITIVES:

2009 – present **Capture Pharmaceuticals, Inc. Chapel Hill, North Carolina**

Co-Founder: Co-founded Capture Pharmaceuticals, Inc. to develop and commercialize orally and topically bioavailable metal chelators for radionuclide decorporation and to ameliorate toxicity due to MRI contrast agents. Co-inventor on intellectual property developed at the University of Kentucky and University of North Carolina through a series of contracts and grants (~$12.5 million total) from the Department of Homeland Security, NIH-NIAID and NIH-NCI (project number 1R41CA203571-01).

2004 – 2015 **Four Tigers, LLC, and Berryceuticals, LLC, Lexington and Paris, Kentucky**

Co-Founder and Chief Scientific Officer: Co-founded Four Tigers, LLC in 2004 and Berryceuticals, LLC in 2007 to develop and commercialize various medical and health products derived from blackberries, the State fruit of Kentucky. Four Tigers' lead products, BerryCare Toothpaste Gum™ and BerryCare Quick Energy Gum™, were launched in June 2013. In July 2013, Four Tigers' first corporate IND for FT1701 was filed and received the go ahead from the FDA. FT1701 is a blackberry chewing gum being developed as a potential botanical drug product for the treatment and prevention of gingivitis. A phase I/II clinical trial at the University of Kentucky began in June 2014 and was funded via an awarded phase II STTR grant (R42DE018839) from NIH-NIDCR with matched funding from the State of Kentucky's competitive SBIR-STTR Matching Funds Program.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.